Oral Solid Dosage Contract Manufacturing Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

Description

Persistence Market Research has recently published an in-depth analysis of the global Oral Solid Dosage Contract Manufacturing Market, offering a comprehensive overview of key market dynamics, growth drivers, challenges, and emerging trends. This report provides valuable insights into the Oral Solid Dosage Contract Manufacturing Market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2024 to 2032.

The global oral solid dosage contract manufacturing market hit US$ 27.7 billion in 2024 and is projected to grow at a CAGR of 5.9%, reaching US$ 43.6 billion by 2032.

Key Insights:

Oral Solid Dosage Contract Manufacturing Market Value (2024): US$ 27.7 Bn
Projected Market Valuation (2032): US$ 43.6 Bn
Global Market Growth Rate (CAGR 2024 to 2032): 5.9%

Oral Solid Dosage Contract Manufacturing Market - Report Scope:

Oral solid dosage forms are widely utilized across the pharmaceutical industry due to their ease of administration, stability, and patient compliance. The report comprehensively explores the market dynamics, including growth drivers, restraints, opportunities, and emerging trends shaping the landscape of oral solid dosage contract manufacturing globally.

Market Growth Drivers:

The oral solid dosage contract manufacturing market is propelled by several factors. Increasing outsourcing by pharmaceutical companies to reduce manufacturing costs and focus on core competencies is a significant driver. Additionally, the rising prevalence of chronic diseases, expanding geriatric population, and the growing demand for generic drugs fuel market growth. Moreover, technological advancements in manufacturing processes and regulatory initiatives supporting contract manufacturing further augment market expansion.

Market Restraints:

Despite the promising growth prospects, certain challenges restrain the oral solid dosage contract manufacturing market. Issues related to quality control, regulatory compliance, and intellectual property protection pose barriers to market entry. Furthermore, fluctuations in raw material prices and the risk of supply chain disruptions impact manufacturing operations, constraining market growth.

Market Opportunities:

The market presents lucrative opportunities for contract manufacturing organizations (CMOs) to diversify their service offerings and expand their global footprint. Collaborations with pharmaceutical companies for niche product development and investing in advanced manufacturing technologies, such as continuous manufacturing and personalized medicine, can unlock new avenues for growth. Moreover, the growing demand for specialty drugs and biologics underscores the need for flexible manufacturing capabilities, creating opportunities for CMOs to cater to specialized formulations and dosage forms.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the oral solid dosage contract manufacturing market?
Which therapeutic segments and regions offer the highest growth potential for contract manufacturers?
How are technological advancements reshaping the competitive landscape of the oral solid dosage contract manufacturing market?
Who are the leading players in the global oral solid dosage contract manufacturing market?
What emerging trends and future prospects are anticipated in the global oral solid dosage contract manufacturing market?

Competitive Intelligence and Business Strategy:

The growing demand for pharmaceutical manufacturing has prompted companies to expand their production capacities. In response, key providers of oral solid dosage contract manufacturing are pursuing strategies like acquisitions and expansions to solidify their market presence. Aurobindo acquired dermatology and oral solids businesses from Sandoz Inc., U.S., complementing Sandoz's focus on complex generics and biosimilars. Piramal Pharma Solutions (PPS) inaugurated a new wing at its riverview site dedicated to producing High Potency Active Pharmaceutical Ingredients (HPAPIs) with Low Occupational Exposure Levels (OELs), enhancing its manufacturing capabilities to meet industry demands.

Key Companies Profiled:

Recipharm
Aenova Holding
Catalent
AbbVie
Patheon N.V. (Thermo Fisher Scientific)
NextPharma
Capsugel (Lonza Group AG)
Aurobindo Pharma Limited
Siegfried AG
Piramal Pharma Solutions
Corden Pharma
Kremoint Pharma Pvt Ltd.
HERMES PHARMA GmbH
Medipaams India Private Limited
Alpex Pharma
Abaris Healthcare Pvt Ltd
Ardena Holdings N.V
Aphena Pharma Solutions
Actiza Pharmaceutical Private Limited
Sunwin Healthcare PVT. LTD
Saffron Medicare PVT. LTD
Kosher Pharmaceuticals
Dr Reddy's Lab
GlaxoSmithKline Plc
Boehringer Ingelheim BioXcellence

Oral Solid Dosage Contract Manufacturing Market Segmentation:

Oral Solid Dosage Contract Manufacturing Market by Dosage Form:

Tablets

Conventional Release

Modified Release

Chewable Tablets

Effervescent Tablets

Capsules

Hard Gelatin Capsules

Soft Gelatin

Capsules/Softgels
Powders & Granules
Lozenges & Pastilles
Gummies

Oral Solid Dosage Contract Manufacturing Market by Mechanism:

Immediate Release
Delayed Release
Controlled Release

Oral Solid Dosage Contract Manufacturing Market by Application:

Drug Product Development
Fill & Finish Product Manufacturing
Packaging /Labelling
Others

Oral Solid Dosage Contract Manufacturing Market by End User:

Big Pharma/Biotech Companies
Smalls & Medium-size Pharma/Biotech Companies
Emerging/virtual Pharma Companies
Nutraceutical Companies

Oral Solid Dosage Contract Manufacturing Market by Region:

North America Oral Solid Dosage Contract Manufacturing Market
Latin America Oral Solid Dosage Contract Manufacturing Market
Europe Oral Solid Dosage Contract Manufacturing Market
South Asia Oral Solid Dosage Contract Manufacturing Market
East Asia Oral Solid Dosage Contract Manufacturing Market
Oceania Oral Solid Dosage Contract Manufacturing Market
Middle East & Africa Oral Solid Dosage Contract Manufacturing Market

Product Code: PMRREP25768

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Pipeline Assessment
4.2. Particle Engineering in Solid Dosage Formulation: Case Studies & Best Practices
4.3. Key Strategies Adopted by market players
4.4. Porters Analysis
4.5. PESTLE Analysis
4.6. Recent Product Launches and Approvals
4.7. Key Regulations
4.8. Value Chain Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. COVID-19 Pandemic
- 5.2.2. Rising Geriatric Population
- 5.2.3. Rising Incidence of Chronic Diseases
- 5.2.4. Patent Expiry and Demand for Generic Drugs
- 5.2.5. Regulatory Policies
- 5.2.6. Advancement in service development
- 5.2.7. Service Availability in different regions
- 5.2.8. Market Consolidation
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunities

6. COVID19 Crisis Analysis

6.1. Current Perspectives on Coronavirus Outbreak
6.2. Current Economic Outlook & Recovery Scenario
6.3. Economic Impact of COVID-19
6.4. COVID-19: 2024 Market Scenario

7. Global Oral Solid Dosage Contract Manufacturing Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Opportunity Analysis, 2024-2032

8. Global Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By Dosage Form

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) & Analysis By Dosage Form, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Dosage Form, 2024-2032
- 8.3.1. Tablets
  - 8.3.1.1. Conventional Release
  - 8.3.1.2. Modified Release
  - 8.3.1.3. Chewable Tablets
  - 8.3.1.4. Effervescent Tablets
- 8.3.2. Capsules
  - 8.3.2.1. Hard Gelatin Capsules
  - 8.3.2.2. Soft Gelatin
- 8.3.3. Capsules/Softgels
- 8.3.4. Powders & Granules
- 8.3.5. Lozenges & Pastilles
- 8.3.6. Gummies
8.4. Market Attractiveness Analysis By Dosage Form

9. Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, by Mechanism

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis Mechanism, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Mechanism, 2024-2032
- 9.3.1. Immediate Release
- 9.3.2. Delayed Release
- 9.3.3. Controlled Release
9.4. Market Attractiveness Analysis By Mechanism

10. Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, by Application

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Application, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2032
- 10.3.1. Drug Product Development
- 10.3.2. Fil & Finish Product Manufacturing
- 10.3.3. Packaging /Labelling
- 10.3.4. Others
10.4. Market Attractiveness Analysis By Application

11. Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, by End User

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2032
- 11.3.1. Big Pharma/Biotech Companies
- 11.3.2. Small & Medium Size Pharma/Biotech Companies
- 11.3.3. Emerging/virtual Pharma Companies
- 11.3.4. Nutraceutical Companies
11.4. Market Attractiveness Analysis By End User

12. Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, by Region

12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis By Region

13. North America Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 13.3.1. By Country
  - 13.3.1.1. U.S.
  - 13.3.1.2. Canada
- 13.3.2. By Dosage Form
- 13.3.3. By Mechanism
- 13.3.4. By Application
- 13.3.5. By End User
13.4. Market Attractiveness Analysis
13.5. Drivers and Restraints - Impact Analysis

14. Latin America Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 14.3.1. By Country
  - 14.3.1.1. Brazil
  - 14.3.1.2. Mexico
  - 14.3.1.3. Argentina
  - 14.3.1.4. Rest of Latin America
- 14.3.2. By Dosage Form
- 14.3.3. By Mechanism
- 14.3.4. By Application
- 14.3.5. By End User
14.4. Market Attractiveness Analysis
14.5. Drivers and Restraints - Impact Analysis

15. Europe Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 15.3.1. By Country
  - 15.3.1.1. Germany
  - 15.3.1.2. Italy
  - 15.3.1.3. France
  - 15.3.1.4. U.K.
  - 15.3.1.5. Spain
  - 15.3.1.6. Netherlands
  - 15.3.1.7. Russia
  - 15.3.1.8. Rest of Europe
- 15.3.2. By Dosage Form
- 15.3.3. By Mechanism
- 15.3.4. By Application
- 15.3.5. By End User
15.4. Market Attractiveness Analysis
15.5. Drivers and Restraints - Impact Analysis

16. South Asia Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 16.3.1. By Country
  - 16.3.1.1. India
  - 16.3.1.2. Thailand
  - 16.3.1.3. Indonesia
  - 16.3.1.4. Malaysia
  - 16.3.1.5. Rest of South Asia
- 16.3.2. By Dosage Form
- 16.3.3. By Mechanism
- 16.3.4. By Application
- 16.3.5. By End User
16.4. Market Attractiveness Analysis
16.5. Drivers and Restraints - Impact Analysis

17. East Asia Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 17.3.1. By Country
  - 17.3.1.1. China
  - 17.3.1.2. Japan
  - 17.3.1.3. South Korea
- 17.3.2. By Dosage Form
- 17.3.3. By Mechanism
- 17.3.4. By Application
- 17.3.5. By End User
17.4. Market Attractiveness Analysis
17.5. Drivers and Restraints - Impact Analysis

18. Oceania Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 18.3.1. By Country
  - 18.3.1.1. Australia
  - 18.3.1.2. New Zealand
- 18.3.2. By Dosage Form
- 18.3.3. By Mechanism
- 18.3.4. By Application
- 18.3.5. By End User
18.4. Market Attractiveness Analysis
18.5. Drivers and Restraints - Impact Analysis

19. Middle East and Africa Oral Solid Dosage Contract Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 19.3.1. By Country
  - 19.3.1.1. GCC Countries
  - 19.3.1.2. Turkey
  - 19.3.1.3. South Africa
  - 19.3.1.4. Rest of Middle East and Africa
- 19.3.2. By Dosage Form
- 19.3.3. By Mechanism
- 19.3.4. By Application
- 19.3.5. By End User
19.4. Market Attractiveness Analysis
19.5. Drivers and Restraints - Impact Analysis

20. Market Structure Analysis

20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
- 20.3.1. Regional Footprint by Players
- 20.3.2. Product Foot print by Players

21. Competition Analysis

21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
- 21.3.1. Recipharm AB
  - 21.3.1.1. Overview
  - 21.3.1.2. Product Portfolio
  - 21.3.1.3. Strategy Overview
- 21.3.2. AbbVie
  - 21.3.2.1. Overview
  - 21.3.2.2. Product Portfolio
  - 21.3.2.3. Strategy Overview
- 21.3.3. Patheon N.V. (Thermo Fisher Scientific)
  - 21.3.3.1. Overview
  - 21.3.3.2. Product Portfolio
  - 21.3.3.3. Strategy Overview
- 21.3.4. Catalent Inc.
  - 21.3.4.1. Overview
  - 21.3.4.2. Product Portfolio
  - 21.3.4.3. Strategy Overview
- 21.3.5. NextPharma
  - 21.3.5.1. Overview
  - 21.3.5.2. Product Portfolio
  - 21.3.5.3. Strategy Overview
- 21.3.6. Capsugel (Lonza Group AG)
  - 21.3.6.1. Overview
  - 21.3.6.2. Product Portfolio
  - 21.3.6.3. Strategy Overview
- 21.3.7. Aurobindo Pharma Limited
  - 21.3.7.1. Overview
  - 21.3.7.2. Product Portfolio
  - 21.3.7.3. Strategy Overview
- 21.3.8. Siegfried AG
  - 21.3.8.1. Overview
  - 21.3.8.2. Product Portfolio
  - 21.3.8.3. Strategy Overview
- 21.3.9. Piramal Pharma Solutions
  - 21.3.9.1. Overview
  - 21.3.9.2. Product Portfolio
  - 21.3.9.3. Strategy Overview
- 21.3.10. Corden Pharma
  - 21.3.10.1. Overview
  - 21.3.10.2. Product Portfolio
  - 21.3.10.3. Strategy Overview
- 21.3.11. Kremoint Pharma Pvt Ltd.
  - 21.3.11.1. Overview
  - 21.3.11.2. Product Portfolio
  - 21.3.11.3. Strategy Overview
- 21.3.12. HERMES PHARMA GmbH
  - 21.3.12.1. Overview
  - 21.3.12.2. Product Portfolio
  - 21.3.12.3. Strategy Overview
- 21.3.13. Medipaams India Private Limited
  - 21.3.13.1. Overview
  - 21.3.13.2. Product Portfolio
  - 21.3.13.3. Strategy Overview
- 21.3.14. Alpex Pharma
  - 21.3.14.1. Overview
  - 21.3.14.2. Product Portfolio
  - 21.3.14.3. Strategy Overview
- 21.3.15. Abaris Healthcare Pvt Ltd
  - 21.3.15.1. Overview
  - 21.3.15.2. Product Portfolio
  - 21.3.15.3. Strategy Overview
- 21.3.16. Ardena Holdings N.V
  - 21.3.16.1. Overview
  - 21.3.16.2. Product Portfolio
  - 21.3.16.3. Strategy Overview
- 21.3.17. Aphena Pharma Solutions
  - 21.3.17.1. Overview
  - 21.3.17.2. Product Portfolio
  - 21.3.17.3. Strategy Overview
- 21.3.18. Actiza Pharmaceutical Private Limited
  - 21.3.18.1. Overview
  - 21.3.18.2. Product Portfolio
  - 21.3.18.3. Strategy Overview
- 21.3.19. Sunwin Healthcare PVT. LTD
  - 21.3.19.1. Overview
  - 21.3.19.2. Product Portfolio
  - 21.3.19.3. Strategy Overview
- 21.3.20. Saffron Medicare PVT. LTD
  - 21.3.20.1. Overview
  - 21.3.20.2. Product Portfolio
  - 21.3.20.3. Strategy Overview
- 21.3.21. Kosher Pharmaceuticals
  - 21.3.21.1. Overview
  - 21.3.21.2. Product Portfolio
  - 21.3.21.3. Strategy Overview
- 21.3.22. Dr Reddy's Lab
  - 21.3.22.1. Overview
  - 21.3.22.2. Product Portfolio
  - 21.3.22.3. Strategy Overview
- 21.3.23. GlaxoSmithKline Plc
  - 21.3.23.1. Overview
  - 21.3.23.2. Product Portfolio
  - 21.3.23.3. Strategy Overview
- 21.3.24. Boehringer Ingelheim BioXcellence
  - 21.3.24.1. Overview
  - 21.3.24.2. Product Portfolio
  - 21.3.24.3. Strategy Overview
- 21.3.25. Aenova Holding
  - 21.3.25.1. Overview
  - 21.3.25.2. Product Portfolio
  - 21.3.25.3. Strategy Overview